Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: Results from two multicentre, blinded, randomised controlled trials

The Lancet Respiratory Medicine

Volumn 2, Issue 6, 2014, Pages 472-486

  Decramer, Marc ^a   Anzueto, Antonio ^b   Kerwin, Edward ^c   Kaelin, Thomas ^d   Richard, Nathalie ^e   Crater, Glenn ^f   Tabberer, Maggie ^g   Harris, Stephanie ^e   Church, Alison ^e  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c Clinical Research Institute of Southern Oregon   (United States)

^d Lowcountry Lung and Critical Care PA   (United States)

^e GLAXOSMITHKLINE   (United States)

^f Clinical Development Aerocrine   (United States)

^g GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

TIOTROPIUM BROMIDE; UMECLIDINIUM; UMECLIDINIUM PLUS VILANTEROL; VILANTEROL; BENZYL ALCOHOL DERIVATIVE; BRONCHODILATING AGENT; CHLOROBENZENE; DRUG COMBINATION; QUINUCLIDINE DERIVATIVE; SCOPOLAMINE DERIVATIVE;

ADULT; ARTICLE; BACKACHE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DRY POWDER INHALER; DYSPNEA; FEMALE; FORCED EXPIRATORY VOLUME; GASTRITIS; HEADACHE; HUMAN; HYPERTENSION; INFLUENZA; LIMB PAIN; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORNING DOSAGE; MULTICENTER STUDY; OROPHARYNX PAIN; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; AGED; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; DRUG EFFECTS; FOLLOW UP; INHALATIONAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; TIME; TREATMENT OUTCOME;

ADMINISTRATION, INHALATION; AGED; BENZYL ALCOHOLS; BRONCHODILATOR AGENTS; CHLOROBENZENES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINUCLIDINES; SCOPOLAMINE DERIVATIVES; TIME FACTORS; TREATMENT OUTCOME;

EID: 84901766003     PISSN: 22132600     EISSN: 22132619     Source Type: Journal    
DOI: 10.1016/S2213-2600(14)70065-7     Document Type: Article

References (34)

1. Celli BR, MacNee W Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946. ATS/ERS Task Force.
2. Brusasco V Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006, 15:32-36.
3. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease, revised 2013 Global Initiative for Chronic Obstructive Lung Disease, (accessed April 18, 2013). http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf.
4. Tashkin DP, Varghese ST Combined treatment with formoterol and tiotropium is more efficacious than treatment with tiotropium alone in patients with chronic obstructive pulmonary disease, regardless of smoking status, inhaled corticosteroid use, baseline severity, or gender. Pulm Pharmacol Ther 2011, 24:147-152.
5. 2-agonists and muscarinic antagonists in COPD. Pulm Pharmacol Ther 2010, 23:257-267.
6. Maltais F, Beck E, Webster D, et al. Four weeks once daily treatment with tiotropium+olodaterol (BI 1744) fixed dose combination compared with tiotropium in COPD patients [abstract 5557]. Eur Respir J 2010, 38(suppl 5):1014s.
7. Mahler DA, D'Urzo A, Bateman ED, et al. Concurrent use of indacaterol plus tiotropium in patients with COPD provides superior bronchodilation compared with tiotropium alone: a randomised, double-blind comparison. Thorax 2012, 67:781-788.
8. Coleman CI, Limone B, Sobieraj DM, et al. Dosing frequency and medication adherence in chronic disease. J Manag Care Pharm 2012, 18:527-539.
9. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G A randomized, double-blind dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012, 106:970-979.
10. Feldman G, Walker RR, Brooks J, Mehta R, Crater G 28-day safety and tolerability of umeclidinium in combination with vilanterol in COPD: a randomized placebo-controlled trial. Pulm Pharmacol Ther 2012, 25:465-471.
11. 2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial. Chest 2012, 142:119-127.
12. Celli B, Crater G, Kilbride S, et al. Once-daily umeclidinium/vilanterol 125/25 μg in COPD: a randomized, controlled study. Chest 2014, published online Jan 2. 10.1378/chest.
13. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A Efficacy and safety of once-daily umeclidinium/vilanterol 62·5/25 μg in COPD. Respir Med 2013, 107:1538-1546.
14. Tiotropium prescribing information Boehringer Ingelheim, (accessed Feb 5, 2013). http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf.
15. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010, 137:138-145.
16. Hankinson JL, Odencrantz JR, Fedan KB Spirometric reference values from a sample of the general US population. Am J Respir Crit Care Med 1999, 159:179-187.
17. Manali ED, Lyberopoulos P, Triantafillidou C, et al. MRC chronic dyspnea scale: relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med 2010, 10:32.
18. Decramer M, Maltais F, Feldman G, et al. Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013, 185:393-399.
19. Mahler DA, Weinberg DH, Wells CK, Feinstein AR The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984, 85:751-758.
20. Howard K, Berry P, Petrillo J, et al. Development of the Shortness of Breath with Daily Activities questionnaire (SOBDA). Value Health 2012, 15:1042-1050.
21. Wilcox TK, Chen WH, Howard KA, et al. Item selection, reliability and validity of the Shortness of Breath with Daily Activities (SOBDA) questionnaire: a new outcome measure for evaluating dyspnea in chronic obstructive pulmonary disease. Health Qual Life Outcomes 2013, 11:196.
22. Watkins ML, Wilcox TK, Tabberer M, et al. Shortness of Breath with Daily Activities questionnaire: validation and responder thresholds in patients with chronic obstructive pulmonary disease. BMJ Open 2013, 3:e003048.
23. Jones PW St George's Respiratory Questionnaire: MCID. COPD 2005, 2:75-79.
24. Clark M, Hofmann A, Tabberer M, Martin S. Development and content vaildity of the COPD device preference questionnaire. Value Health; 14: A255.
25. Siddiqui O, Hung HM, O'Neill R MMRM vs LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharm Stat 2009, 19:227-246.
26. Bland JM, Altman DG Multiple significance tests: the Bonferroni method. BMJ 1995, 310:170.
27. Witek TJ, Mahler DA Meaningful effect size and patterns of response of the transition dyspnea index. J Clin Epidemiol 2003, 56:248-255.
28. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002, 122:47-55.
29. Brusasco V, Hodder R, Miravitlles M, Korducki L, Towse L, Kesten S Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax 2003, 58:399-404.
30. Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J 2013, 42:1484-1494.
31. Buhl R, Dunn LJ, Disdier C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Eur Respir J 2011, 38:797-803.
32. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med 2011, 364:1093-1103.
33. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013, 1:524-533.
34. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med 2013, 1:199-209.